ArticlePharmaceutics2020
Physicochemical, Pharmacokinetic, and Toxicity Evaluation of Soluplus
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- PEG-b-PCL Micelles as Nanocarriers for Poorly Soluble Benzimidazoles: A Comparative Study of Albendazole and Fenbendazole.Molecules (Basel, Switzerland) · 2026Article
- Evaluation of the Drug-Polymer Compatibility and Dissolution Behaviour of Fenbendazole-SoluplusPolymers · 2026Article
- Investigation of Fenbendazole Solubility Using Particle Size Reduction Methods in the Presence of SoluplusPharmaceutics · 2025Article
- Soluplus-TPGS Mixed Micelles as a Delivery System for Brigatinib: Characterization and In Vitro Evaluation.ACS omega · 2024Article
- Efficient Improvement of Eugenol Water Solubility by Spray Drying Encapsulation in SoluplusPharmaceuticals (Basel, Switzerland) · 2024Article
- Comparative Study of TPGS and Soluplus Polymeric Micelles Embedded in Poloxamer 407 In Situ Gels for Intranasal Administration.Gels (Basel, Switzerland) · 2024Article
- Evaluation of Anticancer Efficacy of D-α-Tocopheryl Polyethylene-Glycol Succinate and SoluplusInternational journal of nanomedicine · 2024Article
- Unlocking the potential of stimuli-responsive biomaterials for bone regeneration.Frontiers in pharmacology · 2024Review
- Curcumin-Loaded RH60/F127 Mixed Micelles: Characterization, Biopharmaceutical Characters and Anti-Inflammatory Modulation of Airway Inflammation.Pharmaceutics · 2023Article
- Fabrication of physical and chemical crosslinked hydrogels for bone tissue engineering.Bioactive materials · 2022Review
- Novel Anticancer Strategies.Pharmaceutics · 2021Article
- Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-International journal of nanomedicine · 2021Article
- Preparation and Characterization of MUC-30-Loaded Polymeric Micelles against MCF-7 Cell Lines Using Molecular Docking Methods and In Vitro Study.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Combined Effect of Caspase-Dependent and Caspase-Independent Apoptosis in the Anticancer Activity of Gold Complexes with Phosphine and Benzimidazole Derivatives.Pharmaceuticals (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Fenbendazole (FEN), a broad-spectrum benzimidazole anthelmintic, suppresses cancer cell growth through various mechanisms but has low solubility and achieves low blood concentrations, which leads to low bioavailability. Solubilizing agents are required to prepare poorly soluble drugs for injections; however, these are toxic. To overcome this problem, we designed and fabricated low-toxicity Soluplus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.